KMT2A Amplification in Mixed-Phenotype Acute Leukemia: Immunophenotyping, Cytogenomic Features, and Clinical Correlation.
Source: PubMed, NCBI / U.S. National Library of Medicine
Mixed-phenotype acute leukemia (MPAL) is a rare form of leukemia with a typically unfavorable prognosis. While KMT2A (lysine methyltransferase 2A) rearrangements resulting in gene fusions are common in MPAL, information on KMT2A amplification is lacking. To determine whether KMT2A-amplified MPAL correlates with complex karyotype, TP53 (tumor protein p53) aberration, and shortened survival, aiming to refine risk stratification for better patient management. Flow cytometry, karyotyping, fluorescence in situ hybridization, single nucleotide polymorphism (SNP) microarray, and molecular approaches were used to characterize 3 MPAL cases with KMT2A amplification and clinical correlation. All 3 cases exhibited B-lymphoid/myeloid phenotypes and highly complex karyotypes. Our analysis showed that KMT2A amplifications were intrachromosomal, appearing as homogeneously staining regions (hsr) in 2 cases. In patients 1 and 2, the hsr was located on ring chromosome 7 and chromosome 11, respectively. Interestingly, in patient 3, amplification was found on multiple marker chromosomes. TP53 abnormalities were observed in 2 cases. Single nucleotide polymorphism (SNP) microarray analysis of 1 case revealed oscillating copy number variations on chromosome 11, suggestive of chromoanasynthesis. The amplified region included cancer-related genes KMT2A and DDX6 (DEAD-box helicase 6). Findings from our study show that KMT2A-amplified MPAL is associated with complex karyotypes, TP53 abnormalities, and a
Abstract
Mixed-phenotype acute leukemia (MPAL) is a rare form of leukemia with a typically unfavorable prognosis. While KMT2A (lysine methyltransferase 2A) rearrangements resulting in gene fusions are common in MPAL, information on KMT2A amplification is lacking. To determine whether KMT2A-amplified MPAL correlates with complex karyotype, TP53 (tumor protein p53) aberration, and shortened survival, aiming to refine risk stratification for better patient management. Flow cytometry, karyotyping, fluorescence in situ hybridization, single nucleotide polymorphism (SNP) microarray, and molecular approaches were used to characterize 3 MPAL cases with KMT2A amplification and clinical correlation. All 3 cases exhibited B-lymphoid/myeloid phenotypes and highly complex karyotypes. Our analysis showed that KMT2A amplifications were intrachromosomal, appearing as homogeneously staining regions (hsr) in 2 cases. In patients 1 and 2, the hsr was located on ring chromosome 7 and chromosome 11, respectively. Interestingly, in patient 3, amplification was found on multiple marker chromosomes. TP53 abnormalities were observed in 2 cases. Single nucleotide polymorphism (SNP) microarray analysis of 1 case revealed oscillating copy number variations on chromosome 11, suggestive of chromoanasynthesis. The amplified region included cancer-related genes KMT2A and DDX6 (DEAD-box helicase 6). Findings from our study show that KMT2A-amplified MPAL is associated with complex karyotypes, TP53 abnormalities, and an inferior outcome. Our data may help refine MPAL risk stratification.